HOXA9 methylation detection reagent

Abstract

The invention relates to a lung cancer diagnostic reagent and a kit, and belongs to the field of genetic diagnosis. The reagent or the kit comprises a detection reagent aiming at HOXA9 gene methylation. The detection reagent or the kit provided by the invention has the advantages that the sensitivity in sputa is as high as 74.3 percent; the specificity is as high as 95 percent; the detection sensitivity is higher than that of an existing reported lung cancer tumor marker; the sensitivity in lavage fluid is as high as 61.9 percent; the specificity is as high as 95 percent; the sensitivity particularly on lung adenocarcinoma is greatly improved; and a huge application value is realized on the detection and diagnosis of the lung cancer.

Description

technical field [0001] The invention belongs to the field of gene diagnosis, and more specifically, the invention relates to a lung cancer diagnostic reagent based on human HOXA9 gene methylation or a kit containing the reagent. [0002] technical background [0003] Lung cancer is a malignant tumor of the lung originating from the bronchial mucosa, glands or alveolar epithelium. According to the pathological type, it can be divided into: 1. Small cell lung cancer (SCLC): a special pathological type of lung cancer, with obvious tendency of distant metastasis and poor prognosis, but most patients are sensitive to radiotherapy and chemotherapy. 2. Non-small cell lung cancer (NSCLC): other pathological types of lung cancer other than small cell lung cancer, including squamous cell carcinoma, adenocarcinoma, large cell carcinoma, etc. There are certain differences in biological behavior and clinical course. According to the location of occurrence, it can be divided into: 1. Cen...

AI Technical Summary

Problems solved by technology

(4) Bone scan: the sensitivity of detection of bone metastases of lung cancer is high, but there is a certain false positive rate

[0018] Although some tumor markers related to lung cancer have been found in the prior art, the sensitivity and specificity of these tumor markers cannot meet the demand due to the limitation of detection reagents or detection methods for these tumor markers. Therefore, the current There is still a need for further research in the field of screening methods that can actually be applied to lung cancer

However, although non-invasive screening has unique advantages in sampling, it also has some limitations in other aspects, such as adenocarcinoma in lung cancer, which is difficult to cough up through sputum due to the exfoliated cells in the deep lung , generally speaking, researchers would think that this type of lung cancer is not suitable for non-invasive screening

[0019] On the other hand, even for other types of lung cancer, the currently reported non-invasive screening methods are difficult to meet the requirements of clinical use

Although relevant research has been progressing for many years, there is still no non-invasive screening method for lung cancer that can be promoted to the clinic

Images